

## Letter to Editor

# Annexin 1 and its evolving role in systemic carcinogenesis besides its role in the pathogenesis of breast carcinomas

Shailendra Kapoor

7487 Sherwood Crossing place # 302, Mechanicsville, VA 23111, USA

Received April 30, 2012; accepted June 3, 2012; Epub June 28, 2012; Published July 15, 2012

I read with great interest the recent article by Wu et al in a recent issue of your esteemed journal [1]. The article is highly thought provoking. Interestingly, the past few years have seen the emergence of data that points towards the fact that annexin 1 (ANXA1) plays a significant role in systemic carcinogenesis besides its role in the pathogenesis of breast cancers.

For instance, ANXA1 enhances metastasis in urothelial carcinomas [2]. Similar effects are seen in laryngeal carcinomas where ANXA1 plays a modulatory role in tumor growth as is evident by inhibition of tumor growth in Hep-2 human larynx epidermoid carcinoma cell lines [3]. Similarly, nearly 70% of undifferentiated thyroid carcinomas demonstrate attenuated expression of ANXA1 [4]. On the contrary, up regulation of the protein is seen in papillary thyroid carcinomas.

Similarly, over expression of ANXA1 is seen in nearly 85 % of pancreatic ductal adenocarcinomas [5]. Simultaneously, decreased differentiation is seen in pancreatic adenocarcinomas that demonstrate accentuated expression of ANXA1. Similarly, ANXA1 is expressed along with peroxiredoxin 2 in the saliva of oral cancer patients [6]. Hairy cell leukemia also exhibits up regulation of ANXA1. In fact, ANXA1 serves as a remarkably specific test for hairy cell leukemia [7]. Interestingly, agents such as eurycomanone modulate ANXA1 levels and affect tumor growth in cancers such as pulmonary carcinomas [8].

Clearly, ANXA1 has a major role to play in tumor

growth. Further, large scale studies are needed to further elaborate its effects.

**Address correspondence to:** Dr. Shailendra Kapoor, 74 Crossing place , Mechanicsville, VA 23111, USA. E-mail: shailendrakapoor@yahoo.com

## References

- [1] Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. *Am J Cancer Res* 2012;2(1):104-15.
- [2] Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV, Kang WY, Chen WT, Huang YC, Su YC, Chai CY. Overexpression of annexin 1 in the development and differentiation of urothelial carcinoma. *Kaohsiung J Med Sci* 2012; 28: 145-150.
- [3] Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, Maniglia JV, Raposo LS, Tajara EH, Christian HC, Oliani SM. Annexin 1: differential expression in tumor and mast cells in human larynx cancer. *Int J Cancer* 2007; 120: 2582-2589.
- [4] Petrella A, Festa M, Ercolino SF, Zerilli M, Stassi G, Solito E, Parente L. Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation. *Cancer Biol Ther* 2006; 5: 643-647.
- [5] Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS, Wang K, Xie YQ, Shao YF, Zhao XH. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. *World J Gastroenterol* 2004; 10: 1466-1470.
- [6] Szanto I, Mark L, Bona A, Maasz G, Sandor B, Gelencser G, Turi Z, Gallyas F. High-throughput screening of saliva for early detection of oral cancer: a pilot study. *Technol Cancer Res Treat* 2012; 11: 181-188.
- [7] Falini B, Tiacci E, Liso A, Basso K, Sabattini E,

## Letter to Editor

- Pacini R, Foa R, Pulsoni A, Dalla Favera R, Pileri S. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). *Lancet* 2004; 363: 1869-1870.
- [8] Wong PF, Cheong WF, Shu MH, Teh CH, Chan KL, AbuBakar S. Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28. *Phytomedicine* 2012; 19: 138-144.